Altimmune Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Altimmune Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 2.60 $ to 6.20 $ · Last price: 3.20 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Altimmune Inc ALT | 0.6 | – | 11.9 | -215,138.7 | – | 105.0 | -9.2 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 55.0 | 21.8 | 9.6 | 33.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 5 | -11 | 194 | 841.45 | 202 | 19 | 225 |
| 2017 | 0 | -52 | -46 | -108.77 | -20 | 49 | 63 |
| 2018 | 10 | -43 | -39 | -13.98 | -9 | 48 | 55 |
| 2019 | 6 | -21 | -21 | -1.56 | -10 | 46 | 54 |
| 2020 | 8 | -55 | -49 | -1.91 | -34 | 226 | 245 |
| 2021 | 4 | -97 | -97 | -2.35 | -78 | 199 | 219 |
| 2022 | 0 | -88 | -85 | -1.81 | -63 | 185 | 207 |
| 2023 | 0 | -96 | -88 | -1.66 | -76 | 194 | 211 |
| 2024 | 0 | -103 | -95 | -1.34 | -80 | 124 | 139 |
| 2025 | 0 | -94 | -88 | -1.00 | -68 | 225 | 280 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.33 | – | 0 | -86.50 | -463,600.00 | -18 | -18 |
| 2025: Q1 | -0.26 | – | 0 | 0.00 | -391,500.00 | -17 | -17 |
| 2025: Q2 | -0.27 | – | 0 | 0.00 | -442,920.00 | -20 | -20 |
| 2025: Q3 | -0.21 | – | 0 | 0.00 | -380,280.00 | -12 | -12 |
| 2025: Q4 | -0.27 | – | 0 | 420.00 | -105,223.10 | -19 | -19 |
| 2026: Q1 | -0.18 | – | 0 | -100.00 | – | -21 | -21 |
| 2026: Q2 | -0.12 | 55.60 | – | – | – | -24 | -24 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Breakout & Setup
Risk & Weakness
- Beneish M-Score
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Weakness Cluster
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.59 | -0.65 – -0.53 | 0 | 41.2% | 6 |
| 12/31/2027 | -0.67 | -0.88 – -0.47 | 0 | -13.6% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year -100.0%
- Share count grows by less than 3% a year 23.4%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -164,641.3%
- Gross margin at 40% or higher and without meaningful erosion 100.0%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 238 m net cash
- Operating cash flow covers the profits of the last three years 48 m
- Return on capital at 15% or higher, or up versus two years ago -35.7%
- Insiders hold at least 10% or are net buyers 0.4%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -41.8%
- Exp. sales growth 3Y > 5% -100.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -100.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -39.2%
- ROCE > 15% -35.7%
- Expected return > 10% -100.0%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Durso Jerome Benedict | President and CEO | Buy | 15,000 | 2.95 | 44,250 |
| Jul 31, 2026 | Roberts M Scot | Chief Scientific Officer | Other | 875 | 2.41 | 2,112 |
| Jul 31, 2026 | Weaver Gregory L | Chief Financial Officer | Other | 1,753 | 2.41 | 4,232 |
The company
About the Company
Altimmune, Inc. , a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
- Employees
- 57
- Headquarters
- Gaithersburg, MD
- Address
- 910 Clopper Road, 20878 Gaithersburg, United States
- Phone
- 240 654 1450
- Website
- altimmune.com
- IPO Date
- 10/06/2005
- ISIN
- US02155H2004
- Stock Split
- 1:30 on 09/14/2018
Management
| Name | Title | Birth Year |
|---|---|---|
| Jerome Benedict Durso | Chairman, CEO & President | 1968 |
| M. Scot Roberts Ph.D. | Chief Scientific Officer | 1959 |
| Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer | 1963 |
| Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer | 1956 |
| Andrew Shutterly M.S. | Principal Financial & Accounting Officer and Corporate Controller | 1988 |
| Bertrand Georges Ph.D. | Chief Technology Officer | – |
| Luis Sanay C.F.A. | Vice President of Investor Relations | – |
| Tony Blandin B.S. | Vice President of Quality & Compliance Management | – |
| Robin E. Abrams J.D. | Chief Legal Officer & Corporate Secretary | 1964 |
| Raymond M. Jordt M.B.A., M.S. | Chief Business Officer | 1973 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.